Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) – Equities research analysts at Leerink Swann lowered their FY2017 earnings per share estimates for Achillion Pharmaceuticals in a research note issued to investors on Wednesday. Leerink Swann analyst J. Schwartz now anticipates that the biopharmaceutical company will earn ($0.70) per share for the year, down from their prior forecast of ($0.68). Leerink Swann currently has a “Outperform” rating and a $6.00 target price on the stock. Leerink Swann also issued estimates for Achillion Pharmaceuticals’ FY2018 earnings at ($0.29) EPS and FY2019 earnings at ($0.63) EPS.
A number of other research analysts also recently commented on ACHN. Robert W. Baird increased their target price on Achillion Pharmaceuticals from $5.00 to $10.00 and gave the stock an “outperform” rating in a report on Monday, April 24th. Maxim Group dropped their price target on Achillion Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday, April 25th. Jefferies Group LLC reiterated a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Wednesday, April 26th. Zacks Investment Research cut Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 10th. Finally, BidaskClub upgraded Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $8.25.
TRADEMARK VIOLATION NOTICE: “Leerink Swann Comments on Achillion Pharmaceuticals, Inc.’s FY2017 Earnings (NASDAQ:ACHN)” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/2801755/leerink-swann-comments-on-achillion-pharmaceuticals-inc-s-fy2017-earnings-nasdaqachn.html.
Achillion Pharmaceuticals (NASDAQ ACHN) remained flat at $4.43 on Friday. The company had a trading volume of 395,507 shares. The firm has a 50 day moving average of $4.37 and a 200 day moving average of $4.12. Achillion Pharmaceuticals has a 52-week low of $3.15 and a 52-week high of $9.49. The stock’s market cap is $605.85 million.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). During the same period last year, the business posted ($0.14) EPS.
A number of hedge funds have recently bought and sold shares of the stock. Parametric Portfolio Associates LLC boosted its stake in Achillion Pharmaceuticals by 304.7% in the first quarter. Parametric Portfolio Associates LLC now owns 103,263 shares of the biopharmaceutical company’s stock valued at $435,000 after buying an additional 77,748 shares in the last quarter. Teza Capital Management LLC purchased a new position in shares of Achillion Pharmaceuticals during the first quarter worth about $131,000. UBS Asset Management Americas Inc. raised its position in shares of Achillion Pharmaceuticals by 83.8% in the first quarter. UBS Asset Management Americas Inc. now owns 53,669 shares of the biopharmaceutical company’s stock worth $226,000 after buying an additional 24,471 shares during the last quarter. Canada Pension Plan Investment Board raised its position in shares of Achillion Pharmaceuticals by 4.7% in the first quarter. Canada Pension Plan Investment Board now owns 35,800 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 1,600 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in shares of Achillion Pharmaceuticals by 11.9% in the first quarter. Wells Fargo & Company MN now owns 215,820 shares of the biopharmaceutical company’s stock worth $908,000 after buying an additional 22,931 shares during the last quarter. Hedge funds and other institutional investors own 70.83% of the company’s stock.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.